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Introduction
Gaucher disease (GD), the most common of the lysosomal
storage disorders, results from mutations in the gene for
acid β-glucosidase (glucocerebrosidase, GBA) leading to
insufficient enzyme activity [1]. Glucocerebroside accumu-
lation in the lysosomes of various cell types is responsible
for the clinical manifestations of GD, which may include
hepatomegaly, splenomegaly, anemia, thrombocytopenia,
and bone marrow infiltration by lipid-engorged “Gaucher
cells.” Occurring panethnically, type 1 (non-neuronopathic)
is the most prevalent form of GD, while the less frequent
type 2 (acute neuronopathic) and type 3 (chronic neuro-
nopathic) are characterized by neurological involvement.
More than half of type 1 patients are diagnosed in childhood
and an earlier age of onset is indicative of more severe
disease due to its progressive nature.
Affecting both the marrow and mineral compartments,
GD-related bone disease is the most significant cause of
morbidity and long-term disability for patients. GD-related
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San Francisco, CA, USAbone disease in children is a major cause for concern as it
puts them at risk of developing irreversible and debilitating
bone complications and interferes with normal growth and
achievement of optimal bone mass during a critical period
of growth. Timely initiation of appropriate disease manage-
ment is necessary to avoid serious long-term complications
such as growth retardation, osteoporosis, and fractures, and
includes an initial radiological assessment and ongoing
monitoringofboththebonemarrowandmineralcomponents.
General guidelines for the monitoring of skeletal disease in
children with type 1 GD recommend magnetic resonance
imaging (MRI) of the spine and femora; radiography of the
spine (when clinically indicated), chest, pelvis, and long
bones; and dual-energy X-ray absorptiometry (DXA) of the
spine and hips at baseline and every 12–24 months [2, 3].
However, these recommendations require further clarifica-
tion in view of the challenges associated with their use in
children with GD, especially since the use of conventional
radiography is limited by a high burden of radiation and
lack of sensitivity and specificity.
The current standard of care for type 1 GD is enzyme
replacement therapy (ERT) with imiglucerase (Cerezyme®;
GenzymeCorporation,Cambridge,MA,USA).Oralsubstrate
reduction therapy with miglustat (Zavesca®; Actelion, San
Francisco, CA, USA) is also available for the treatment of
patients with mild to moderate GD for whom ERT is not
an option. The availability of therapy that may prevent or
reverse GD-related bone disease heightens the need for early
diagnosis and initiation of disease management in children.
AWorking Group of international experts met in October
2006 to recommend evidence- and consensus-based guide-
lines to facilitate the assessment and monitoring of bone
disease in children with type 1 or type 3 GD.
Assessment of bone marrow infiltration in pediatric
Gaucher patients by MRI
Magnetic resonance imaging, the most widely used and
accepted method of assessing and evaluating changes in
bone marrow,isthe method of choice formonitoring marrow
displacement in adults with GD. This technique has also
been used in children with GD to qualitatively evaluate and
characterize bone marrow infiltration by Gaucher cells [4].
Advantages of MRI include widely available technology,
semi-quantitative assessments, ease of measurement, high
sensitivity, and lack of associated ionizing radiation.
The displacement of fatty marrow by Gaucher cells is
best detected by T1-weighted MRI and appears as an abnor-
mally low-intensity signal, which is unique compared with
the triglyceride signal. Following ERT with imiglucerase in
patients with GD, the responding bone marrow shows
increased triglyceride content and an increase (brightening)
in the bone marrow signal. T2-weighted fat saturation or
short tau inversion recovery (STIR) sequences are the most
sensitive for the detection of additional bone marrow com-
plications of GD, including irreversible avascular necrosis.
Interpretation of MRI measurements with respect
to the physiologic conversion of bone marrow
Neither the chronology of pediatric GD bone marrow
involvement and its variations nor the impact of delayed
skeletal maturation on the conversion of hematopoietic to
fatty marrow in children with GD are known. Knowledge
of thetypical conversion patterns of bonemarrow in Gaucher
patients on MRI by age group as well as the availability of
normative pediatric MRI data will eventually allow a more
clinically useful interpretation of MRI-derived data. MR
images of children with GD should be interpreted in com-
parison with normal physiological conversion patterns,
especially in very young children whose low signal due to a
high percentage of red marrow appears similar to patholog-
ically infiltrated bone marrow. The potential contributions of
therapytoobservedchangesinbonemarrow infiltrationmust
also be considered.
Clinical interpretation of MRI measurements
Numerous semi-quantitative scoring systems have been
developed for the evaluation of bone marrow infiltration in
adult Gaucher patients, including the Rosenthal score, the
Düsseldorf Gaucher score, the Terk classification, the verte-
bra-disc-ratio, and the bone marrow burden (BMB) score [5].
Dixon Quantitative Chemical Shift Imaging (QCSI), a
quantitative MR-based technique, reports the displacement
of triglyceride-containing marrow by Gaucher cells as a fat
fraction. The BMB scoring method is preferred over the
other available scoring systems as it includes measurements
of both lumbar spine and femur, key anatomical sites of
Gaucher cell infiltration, and has been validated against
other methods and applied in multiple studies [6, 7].
Although numerous studies on age-related distribution of
fat in bone marrow in children have been performed, normal
QCSI vertebral fat fractions have yet to be established for
children.
Use of sedation
Children between birth and the age of 6 years usually
require sedation or a general anesthetic for successful
examination by MRI. In the absence of local “best practice”
protocols, MRI examinations of children with GD should
be carried out in accordance with the guidelines established
by the American Academy of Pediatrics and the American
Society of Anesthesiologists.
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99mTc-Sestamibi accumulation in the bone marrow has been
used to assess the severity of bone marrow infiltration by
Gaucher cells in adults and results correlate highly with
other indicators of systemic disease burden. Despite this
technique’s independence from the influence of bone
marrow conversion, scintigraphic images are less spatially
resolved than MR images, the radiation burden to the
growing child is significant, and pediatric normal controls
do not exist. Therefore, at present
99mTc-Sestamibi is not an
acceptable alternative for assessing or monitoring bone
marrow infiltration.
Assessment of BMD in pediatric Gaucher patients
by DXA
Widely available, relatively inexpensive, and involving low
ionizing radiation exposure, DXA is safe, noninvasive,
rapid, painless, and the preferred technique for the diagnosis
of osteopenia and osteoporosis in adults. DXA is routinely
used to evaluate bone mineral density (BMD) in patients
with GD and is capable of providing a quantitative assess-
ment of bone involvement and monitoring changes in bone
density in response to therapy. DXA is potentially useful for
the evaluation of BMD in children with GD, although
specific technical and practical issues need to be considered.
Technical aspects of DXA measurements in children
Due to the two-dimensional nature of DXA technology,
DXA measurements are highly influenced by bone size as
well as by bone age and pubertal stage. Therefore, small
bone size may be misinterpreted as a low BMD. Since
growth retardation, pubertal delay, and decreased body mass
are common problems in pediatric GD and may distort
measured BMD, these factors must be considered when
interpreting the DXA-derived data. With serial measure-
ments in the presence or absence of therapy, normal growth
in a child with initially small bones should not be perceived
as a false increase in BMD. Additional confounding factors
for DXA scans of the hip or lumbar spine include avascular
necrosis and vertebral compression fractures respectively,
both of which may occur with GD. Awareness of these
potential influences on BMD measurements obtained by
DXA can prevent misinterpretation and improve the clinical
usefulness of these data.
Clinical interpretation of DXA measurements
In adults DXA measurements are reported as T-scores, which
represent the number of standard deviations from the mean
BMD of a reference group of normal gender-matched indi-
viduals in the age range (3rd decade) during which BMD
peaks. T-scores are not applicable for individuals under the
age of 20 years; measurements made in children are reported
as age- and gender-matched Z-scores. Although Z-scores
cannot diagnose osteopenia or osteoporosis, a Z-score below
−2.0 or above 0.0 represents a value outside the normal range.
The clinical usefulness of DXA in children with GD
depends on access to appropriate software for data analysis,
normative pediatric data, and familiarity with the correct
methods of reporting measurements. The major DXA manu-
facturers currently provide pediatric reference data of BMD
versus chronological age, and gender- and ethnicity-specific
reference data for healthy European and North American
children have recently been published for the assessment of
BMD measured by DXA [8, 9]. However, standards for
adjusting BMD on the basis of bone size, pubertal stage,
skeletal maturity, and body composition are also needed.
Furthermore, correlations between DXA-derived data and the
likelihood of developing fractures would increase the usefulness
of DXA for the evaluation of BMD in children with GD.
Quantitative computed tomography: an alternative to DXA?
Unlike DXA, quantitative computed tomography (QCT) can
assess bone density independently of bone size, allowing
measurement of the actual volumetric density of a specific
compartment and eliminating the potentially confounding
factors of growth retardation and pubertal delay observed in
some pediatric Gaucher patients. However, few pediatric
studies using this technique and no standard analyses are
available, and QCT of the spine results in considerable
radiation exposure. Therefore, QCT currently cannot be
recommended for use in children.
Recommendations
We recommend the following guidelines as appropriate for
monitoring skeletal manifestations in children with type 1
or type 3 GD.
Performing measurements with MRI
1. Perform assessments at centers with MRI expertise in
children.
2. Assess anatomical sites including a substantial part of
the preferably axial bone marrow compartment (femur,
pelvis, and spine) at baseline and at least every 2 years,
ideally annually.
3. T1 and either T2 or STIR sequences are recommended
for routine evaluation, and STIR sequences are recom-
mended to detect complications.
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1 Magnetic resonance images of children with GD should
be interpreted in comparison with normal physiological
conversion patterns.
2. The potential contributions of therapy to observed
changes in bone marrow infiltration must be considered.
Use of sedation for MRI measurements
The American Academy of Pediatrics and the American
Society of Anesthesiologists provide guidance to facilitate
theadministration ofsedation, ifneeded,inthesafestmanner
possible.
Performing measurements with DXA
1. Perform assessments at centers with DXA expertise in
children and where normal pediatric data are available.
2. Assess lumbar spine and proximal femur and the entire
body at baseline and annually thereafter, provided that
normal pediatric reference standards are available.
3. Perform serial scans on the same DXA machine and
analyze with the appropriate pediatric option.
Clinical interpretation of DXA measurements
Dual-energy X-ray absorptiometry measurements from
children (males or females < 20 years of age) with GD
should be interpreted and reported in accordance with the
recommendations and caveats provided by the International
Society for Clinical Densitometry [10]:
1. Z-scores must be used; T-scores should not be used in
children.
2. Z-scores must be interpreted using the best available
pediatric databases of age-, gender-, and ethnicity-
matched controls. Reports should cite the reference
database used.
3. Terminology such as “low bone density for chronologic
age” or “below the expected range for age” may be used
if the Z-score < −2.0.
4. The diagnosis cannot be made on the basis of densi-
tometric criteria alone.
5. The value of BMD to predict the likelihood of fractures
in children has not been clearly determined.
6. No agreement exists on standards for adjusting BMD
for factors such as bone size, pubertal stage, skeletal
maturity, and body composition. If adjustments are
made, they should be clearly stated in the report.
7. Deviation from standard adult analysis protocols, such
as use of low-density software and manual adjustment
of the region of interest, should be stated in the report
for the accurate comparison of DXA-derived data.
Role of conventional radiography
Although widely available and relatively inexpensive, we do
not recommend the routine or exclusive use of conventional
radiography due to its high burden of radiation and lack of
sensitivity and specificity.
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